Insider Transactions in Q2 2022 at Guardant Health, Inc. (GH)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2022
|
Ian T Clark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,198
+50.0%
|
-
|
|
Jun 15
2022
|
Stanley J Meresman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,814
+23.6%
|
-
|
|
Jun 15
2022
|
Samir Kaul Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,814
+23.6%
|
-
|
|
Jun 15
2022
|
Vijaya Gadde Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,814
+21.77%
|
-
|
|
Jun 15
2022
|
Chris Freeman Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,688
-34.6%
|
$64,144
$38.42 P/Share
|
|
Jun 15
2022
|
Chris Freeman Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,879
+50.0%
|
-
|
|
Jun 15
2022
|
Bahija Jallal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,814
+19.67%
|
-
|
|
May 15
2022
|
Craig Eagle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,286
-34.6%
|
$45,010
$35.91 P/Share
|
|
May 15
2022
|
Craig Eagle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+50.0%
|
-
|
|
Apr 15
2022
|
John G. Saia Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-7.66%
|
$78,242
$71.99 P/Share
|